JP2012518598A - ピリミドピリミドインダゾール誘導体 - Google Patents
ピリミドピリミドインダゾール誘導体 Download PDFInfo
- Publication number
- JP2012518598A JP2012518598A JP2011535742A JP2011535742A JP2012518598A JP 2012518598 A JP2012518598 A JP 2012518598A JP 2011535742 A JP2011535742 A JP 2011535742A JP 2011535742 A JP2011535742 A JP 2011535742A JP 2012518598 A JP2012518598 A JP 2012518598A
- Authority
- JP
- Japan
- Prior art keywords
- group
- pyrimido
- indazol
- alkyl group
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 533
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 172
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 161
- 125000005843 halogen group Chemical group 0.000 claims abstract description 146
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 144
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 50
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 47
- 125000003118 aryl group Chemical group 0.000 claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 44
- 201000011510 cancer Diseases 0.000 claims abstract description 39
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 37
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 32
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 28
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 11
- -1 perhydro-1,4-diazepinyl group Chemical group 0.000 claims description 481
- 238000002360 preparation method Methods 0.000 claims description 290
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 136
- QSVSMNAYVRURDO-UHFFFAOYSA-N 6,7-dihydroindazol-5-one Chemical compound O=C1CCC2=NN=CC2=C1 QSVSMNAYVRURDO-UHFFFAOYSA-N 0.000 claims description 120
- 125000001424 substituent group Chemical group 0.000 claims description 119
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 94
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 55
- 230000001093 anti-cancer Effects 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 48
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 29
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 26
- 150000001204 N-oxides Chemical class 0.000 claims description 25
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 23
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 20
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 19
- 150000002148 esters Chemical class 0.000 claims description 19
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 16
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 15
- 229940127093 camptothecin Drugs 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 102000014150 Interferons Human genes 0.000 claims description 14
- 108010050904 Interferons Proteins 0.000 claims description 14
- 125000001931 aliphatic group Chemical group 0.000 claims description 14
- 125000004043 oxo group Chemical group O=* 0.000 claims description 14
- 125000004434 sulfur atom Chemical group 0.000 claims description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 229940127084 other anti-cancer agent Drugs 0.000 claims description 13
- 229910052697 platinum Inorganic materials 0.000 claims description 13
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 12
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 12
- 229940100198 alkylating agent Drugs 0.000 claims description 11
- 239000002168 alkylating agent Substances 0.000 claims description 11
- 230000000340 anti-metabolite Effects 0.000 claims description 11
- 229940100197 antimetabolite Drugs 0.000 claims description 11
- 239000002256 antimetabolite Substances 0.000 claims description 11
- 229960005277 gemcitabine Drugs 0.000 claims description 11
- 229940079322 interferon Drugs 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 11
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 11
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 10
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 10
- 125000001041 indolyl group Chemical group 0.000 claims description 10
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 10
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 10
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 9
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 229960002949 fluorouracil Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 7
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 7
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 7
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 7
- 229960000684 cytarabine Drugs 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 6
- 239000003972 antineoplastic antibiotic Substances 0.000 claims description 6
- 230000008512 biological response Effects 0.000 claims description 6
- 229960004562 carboplatin Drugs 0.000 claims description 6
- 229960003668 docetaxel Drugs 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960004768 irinotecan Drugs 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 229960005395 cetuximab Drugs 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
- 229960004679 doxorubicin Drugs 0.000 claims description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 5
- 229960005420 etoposide Drugs 0.000 claims description 5
- 229960002584 gefitinib Drugs 0.000 claims description 5
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 5
- 229960004338 leuprorelin Drugs 0.000 claims description 5
- 239000003607 modifier Substances 0.000 claims description 5
- 229960001756 oxaliplatin Drugs 0.000 claims description 5
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 229960004641 rituximab Drugs 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- 229960001674 tegafur Drugs 0.000 claims description 5
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 5
- 229960000303 topotecan Drugs 0.000 claims description 5
- 229960000575 trastuzumab Drugs 0.000 claims description 5
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 4
- 108010024976 Asparaginase Proteins 0.000 claims description 4
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 claims description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 4
- 108010092160 Dactinomycin Proteins 0.000 claims description 4
- 108010019673 Darbepoetin alfa Proteins 0.000 claims description 4
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 4
- 108010069236 Goserelin Proteins 0.000 claims description 4
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 4
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 4
- 229920001491 Lentinan Polymers 0.000 claims description 4
- 108010000817 Leuprolide Proteins 0.000 claims description 4
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 4
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229960003901 dacarbazine Drugs 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 4
- 229960002411 imatinib Drugs 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 239000000367 immunologic factor Substances 0.000 claims description 4
- 229940115286 lentinan Drugs 0.000 claims description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 229960004857 mitomycin Drugs 0.000 claims description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
- 229960001221 pirarubicin Drugs 0.000 claims description 4
- 108010001062 polysaccharide-K Proteins 0.000 claims description 4
- 229960004964 temozolomide Drugs 0.000 claims description 4
- 229960001196 thiotepa Drugs 0.000 claims description 4
- 229950009811 ubenimex Drugs 0.000 claims description 4
- 229960003048 vinblastine Drugs 0.000 claims description 4
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 4
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 3
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims description 3
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 claims description 3
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 3
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims description 3
- NKGPJODWTZCHGF-UHFFFAOYSA-N 9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound OC1C(O)C(CO)OC1N1C(NC=NC2=S)=C2N=C1 NKGPJODWTZCHGF-UHFFFAOYSA-N 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- SHRRGLBOQDUUJT-UHFFFAOYSA-N C1=C2CN(C)CC2=CC=C1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CC=N1 Chemical compound C1=C2CN(C)CC2=CC=C1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CC=N1 SHRRGLBOQDUUJT-UHFFFAOYSA-N 0.000 claims description 3
- WPFUZJHILYNHRJ-UHFFFAOYSA-N C1=C2CN(C)CCC2=CC=C1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC=CC=N1 Chemical compound C1=C2CN(C)CCC2=CC=C1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC=CC=N1 WPFUZJHILYNHRJ-UHFFFAOYSA-N 0.000 claims description 3
- CFITXYMMVMTWIT-UHFFFAOYSA-N C1=C2CN(C)CCC2=CC=C1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CC=N1 Chemical compound C1=C2CN(C)CCC2=CC=C1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CC=N1 CFITXYMMVMTWIT-UHFFFAOYSA-N 0.000 claims description 3
- WDGRAELSBPIACJ-UHFFFAOYSA-N C1=CC(CN(C)C)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1=CC(CN(C)C)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 WDGRAELSBPIACJ-UHFFFAOYSA-N 0.000 claims description 3
- FJMDNDUFYGIWQA-UHFFFAOYSA-N C=1C=C2CN(C)CCC2=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC=CC=N1 Chemical compound C=1C=C2CN(C)CCC2=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC=CC=N1 FJMDNDUFYGIWQA-UHFFFAOYSA-N 0.000 claims description 3
- AAZZYZIZOZQGAV-UHFFFAOYSA-N C=1C=C2CN(C)CCC2=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CC=N1 Chemical compound C=1C=C2CN(C)CCC2=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CC=N1 AAZZYZIZOZQGAV-UHFFFAOYSA-N 0.000 claims description 3
- DQFINAQUYZUXBX-UHFFFAOYSA-N C=1C=C2N(CCN(C)C)CCC2=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CS1 Chemical compound C=1C=C2N(CCN(C)C)CCC2=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CS1 DQFINAQUYZUXBX-UHFFFAOYSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 3
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 3
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 3
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 3
- 102000006992 Interferon-alpha Human genes 0.000 claims description 3
- 108010047761 Interferon-alpha Proteins 0.000 claims description 3
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 3
- 108090000467 Interferon-beta Proteins 0.000 claims description 3
- 102000003996 Interferon-beta Human genes 0.000 claims description 3
- AFLXUQUGROGEFA-UHFFFAOYSA-N Nitrogen mustard N-oxide Chemical group ClCC[N+]([O-])(C)CCCl AFLXUQUGROGEFA-UHFFFAOYSA-N 0.000 claims description 3
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 claims description 3
- 229920002305 Schizophyllan Polymers 0.000 claims description 3
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims description 3
- 229960004176 aclarubicin Drugs 0.000 claims description 3
- 108700025316 aldesleukin Proteins 0.000 claims description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 3
- 229960002594 arsenic trioxide Drugs 0.000 claims description 3
- 229960000997 bicalutamide Drugs 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- 229960001467 bortezomib Drugs 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- 229960004117 capecitabine Drugs 0.000 claims description 3
- 229960003261 carmofur Drugs 0.000 claims description 3
- 229960005243 carmustine Drugs 0.000 claims description 3
- 229960000640 dactinomycin Drugs 0.000 claims description 3
- 229960005029 darbepoetin alfa Drugs 0.000 claims description 3
- 229960000975 daunorubicin Drugs 0.000 claims description 3
- 108010017271 denileukin diftitox Proteins 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- 229960001433 erlotinib Drugs 0.000 claims description 3
- 229960000390 fludarabine Drugs 0.000 claims description 3
- 229960002074 flutamide Drugs 0.000 claims description 3
- 229960002913 goserelin Drugs 0.000 claims description 3
- 229960001330 hydroxycarbamide Drugs 0.000 claims description 3
- 229960000908 idarubicin Drugs 0.000 claims description 3
- 229940095009 interferon gamma-1a Drugs 0.000 claims description 3
- 229960001388 interferon-beta Drugs 0.000 claims description 3
- 229940047124 interferons Drugs 0.000 claims description 3
- 229960001924 melphalan Drugs 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims description 3
- 229960001420 nimustine Drugs 0.000 claims description 3
- 229960003407 pegaptanib Drugs 0.000 claims description 3
- 229960002340 pentostatin Drugs 0.000 claims description 3
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 3
- 229960000624 procarbazine Drugs 0.000 claims description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 229960002185 ranimustine Drugs 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 229960001727 tretinoin Drugs 0.000 claims description 3
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims description 3
- 229960000653 valrubicin Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical group C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 3
- 229960004355 vindesine Drugs 0.000 claims description 3
- 229960002066 vinorelbine Drugs 0.000 claims description 3
- QQLFIKWLMJCBMK-UHFFFAOYSA-N 6-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]-17-pyridin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C1CN(C)CCN1C(C(=C1)C)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CC=4)C4=CC=CC=C4C3=NC2=N1 QQLFIKWLMJCBMK-UHFFFAOYSA-N 0.000 claims description 2
- TWJRQQONNKGBCY-UHFFFAOYSA-N C1=C(C)C(OCCN(C)C)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1=C(C)C(OCCN(C)C)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 TWJRQQONNKGBCY-UHFFFAOYSA-N 0.000 claims description 2
- KFNOHYFANBPHSR-UHFFFAOYSA-N C1=C2CN(C)CCC2=CC=C1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CS1 Chemical compound C1=C2CN(C)CCC2=CC=C1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CS1 KFNOHYFANBPHSR-UHFFFAOYSA-N 0.000 claims description 2
- OVMQGQFFIOGXQT-UHFFFAOYSA-N C1=CC(CCN(C)C)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1=CC(CCN(C)C)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 OVMQGQFFIOGXQT-UHFFFAOYSA-N 0.000 claims description 2
- YFFSCPGWRGCKMJ-UHFFFAOYSA-N C1=CC(OCCCN(C)C)=CC=C1NC1=NC=C2C(=O)N3N(C=4SC=CN=4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1=CC(OCCCN(C)C)=CC=C1NC1=NC=C2C(=O)N3N(C=4SC=CN=4)C4=CC=CC=C4C3=NC2=N1 YFFSCPGWRGCKMJ-UHFFFAOYSA-N 0.000 claims description 2
- BZSAWNIUFWPRBB-UHFFFAOYSA-N C1CN(C)CCC1(C)C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1CN(C)CCC1(C)C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 BZSAWNIUFWPRBB-UHFFFAOYSA-N 0.000 claims description 2
- FSHPPKALJNIDIX-UHFFFAOYSA-N C1CN(C)CCN1C(C(=C1)C)=CC=C1NC1=NC=C2C(=O)N3N(C4=CSC=C4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1CN(C)CCN1C(C(=C1)C)=CC=C1NC1=NC=C2C(=O)N3N(C4=CSC=C4)C4=CC=CC=C4C3=NC2=N1 FSHPPKALJNIDIX-UHFFFAOYSA-N 0.000 claims description 2
- JTQFXCLPVGVWSN-UHFFFAOYSA-N C1CN(C)CCN1C(C(=C1)C)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1CN(C)CCN1C(C(=C1)C)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 JTQFXCLPVGVWSN-UHFFFAOYSA-N 0.000 claims description 2
- VOHXROKYBSQMEZ-UHFFFAOYSA-N C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CC=4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CC=4)C4=CC=CC=C4C3=NC2=N1 VOHXROKYBSQMEZ-UHFFFAOYSA-N 0.000 claims description 2
- XNDLXLJDPPMXOX-UHFFFAOYSA-N C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 XNDLXLJDPPMXOX-UHFFFAOYSA-N 0.000 claims description 2
- FKQNLQGDJBEYFS-UHFFFAOYSA-N C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CSC=4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CSC=4)C4=CC=CC=C4C3=NC2=N1 FKQNLQGDJBEYFS-UHFFFAOYSA-N 0.000 claims description 2
- MXEVOSUOLANYCZ-UHFFFAOYSA-N C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4SC=CN=4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4SC=CN=4)C4=CC=CC=C4C3=NC2=N1 MXEVOSUOLANYCZ-UHFFFAOYSA-N 0.000 claims description 2
- PKUDTXMDHXMXLV-FQEVSTJZSA-N C1[C@@H](N(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1[C@@H](N(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 PKUDTXMDHXMXLV-FQEVSTJZSA-N 0.000 claims description 2
- KYXNIEYRJSDLEJ-UHFFFAOYSA-N C=1C=C2C(C)(C)N(C)CCC2=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CC=N1 Chemical compound C=1C=C2C(C)(C)N(C)CCC2=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CC=N1 KYXNIEYRJSDLEJ-UHFFFAOYSA-N 0.000 claims description 2
- KWGBOISPRDLOHG-UHFFFAOYSA-N C=1C=C2CN(C)CCC2=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CS1 Chemical compound C=1C=C2CN(C)CCC2=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CS1 KWGBOISPRDLOHG-UHFFFAOYSA-N 0.000 claims description 2
- XOILXHXPJAOPBV-UHFFFAOYSA-N C=1C=C2N(CCN(C)C)CCOC2=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CS1 Chemical compound C=1C=C2N(CCN(C)C)CCOC2=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CS1 XOILXHXPJAOPBV-UHFFFAOYSA-N 0.000 claims description 2
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 claims description 2
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 claims description 2
- 108010061174 Thyrotropin Proteins 0.000 claims description 2
- 102000011923 Thyrotropin Human genes 0.000 claims description 2
- 229960005310 aldesleukin Drugs 0.000 claims description 2
- 229960002459 alefacept Drugs 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 229960002932 anastrozole Drugs 0.000 claims description 2
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002923 denileukin diftitox Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 229960002258 fulvestrant Drugs 0.000 claims description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 2
- 229960001428 mercaptopurine Drugs 0.000 claims description 2
- 229960005485 mitobronitol Drugs 0.000 claims description 2
- 229950007221 nedaplatin Drugs 0.000 claims description 2
- 239000002534 radiation-sensitizing agent Substances 0.000 claims description 2
- 229950010372 sobuzoxane Drugs 0.000 claims description 2
- 229960000874 thyrotropin Drugs 0.000 claims description 2
- 230000001748 thyrotropin Effects 0.000 claims description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- DJHJYOHPYOEMRD-UHFFFAOYSA-N C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CC=4)C4=CC(O)=CC=C4C3=NC2=N1 Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CC=4)C4=CC(O)=CC=C4C3=NC2=N1 DJHJYOHPYOEMRD-UHFFFAOYSA-N 0.000 claims 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
- 229960003349 pemetrexed disodium Drugs 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 101150040313 Wee1 gene Proteins 0.000 abstract description 19
- 230000002401 inhibitory effect Effects 0.000 abstract description 19
- 102000020233 phosphotransferase Human genes 0.000 abstract description 12
- 238000001959 radiotherapy Methods 0.000 abstract description 12
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 11
- 238000002512 chemotherapy Methods 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 description 361
- 239000007787 solid Substances 0.000 description 276
- 238000005160 1H NMR spectroscopy Methods 0.000 description 168
- HFYDYVJLUIFJCA-UHFFFAOYSA-N 17-methyl-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C12=CC=CC=C2N(C)N2C1=NC1=NC(SC)=NC=C1C2=O HFYDYVJLUIFJCA-UHFFFAOYSA-N 0.000 description 144
- 229910052739 hydrogen Inorganic materials 0.000 description 118
- 239000000243 solution Substances 0.000 description 88
- 238000006243 chemical reaction Methods 0.000 description 85
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 84
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 68
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 58
- VVMXAXVHQDIGRF-UHFFFAOYSA-N 3-methyl-4-(4-methylpiperazin-1-yl)aniline Chemical compound C1CN(C)CCN1C1=CC=C(N)C=C1C VVMXAXVHQDIGRF-UHFFFAOYSA-N 0.000 description 53
- 238000000034 method Methods 0.000 description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- MSPHSQDLDJOPCH-UHFFFAOYSA-N 6-methylsulfanyl-17-(1,3-thiazol-2-yl)-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CS1 MSPHSQDLDJOPCH-UHFFFAOYSA-N 0.000 description 44
- RNYUUGCLRUASAE-UHFFFAOYSA-N 6-methylsulfanyl-17-pyrimidin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CC=N1 RNYUUGCLRUASAE-UHFFFAOYSA-N 0.000 description 44
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 42
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 32
- 230000002829 reductive effect Effects 0.000 description 30
- SPIWCPNTFXPHNV-UHFFFAOYSA-N 6-methylsulfanyl-17-pyridin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC=CC=N1 SPIWCPNTFXPHNV-UHFFFAOYSA-N 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 239000002585 base Substances 0.000 description 28
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 230000001225 therapeutic effect Effects 0.000 description 24
- 239000002904 solvent Substances 0.000 description 22
- 101150012716 CDK1 gene Proteins 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- 238000010898 silica gel chromatography Methods 0.000 description 18
- MOZNZNKHRXRLLF-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)aniline Chemical compound C1CN(C)CCN1C1=CC=C(N)C=C1 MOZNZNKHRXRLLF-UHFFFAOYSA-N 0.000 description 17
- 125000006239 protecting group Chemical group 0.000 description 17
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 16
- 239000012153 distilled water Substances 0.000 description 16
- 125000000524 functional group Chemical group 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- 125000003277 amino group Chemical group 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- MJBWDEQAUQTVKK-IAGOWNOFSA-N aflatoxin M1 Chemical compound C=1([C@]2(O)C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O MJBWDEQAUQTVKK-IAGOWNOFSA-N 0.000 description 12
- 229910052801 chlorine Inorganic materials 0.000 description 12
- 125000001309 chloro group Chemical group Cl* 0.000 description 12
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 11
- 238000007796 conventional method Methods 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- 239000012442 inert solvent Substances 0.000 description 11
- 238000001802 infusion Methods 0.000 description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 10
- 125000001841 imino group Chemical group [H]N=* 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 230000001590 oxidative effect Effects 0.000 description 10
- 230000035484 reaction time Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 125000001153 fluoro group Chemical group F* 0.000 description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 9
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 9
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 7
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 229910002091 carbon monoxide Inorganic materials 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000010253 intravenous injection Methods 0.000 description 7
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 6
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 6
- PZSISEFPCYMBDL-UHFFFAOYSA-N 2-bromo-3-methylpyridine Chemical compound CC1=CC=CN=C1Br PZSISEFPCYMBDL-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- RFCFUYHIFUJWBU-UHFFFAOYSA-N 4-[[1-(3-methylpyridin-2-yl)indazol-3-yl]amino]-2-methylsulfanylpyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C(NC=2C3=CC=CC=C3N(C=3C(=CC=CN=3)C)N=2)=N1 RFCFUYHIFUJWBU-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000007800 oxidant agent Substances 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 208000000649 small cell carcinoma Diseases 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 5
- KWJUZUNIKDFJJR-UHFFFAOYSA-N N1=CN=CC2=C1N=C1N(NC=3C=CC=CC13)C2=O Chemical compound N1=CN=CC2=C1N=C1N(NC=3C=CC=CC13)C2=O KWJUZUNIKDFJJR-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 5
- 102000013415 peroxidase activity proteins Human genes 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 4
- PWHRVVMNFQGSJQ-UHFFFAOYSA-N 2-methyl-3,4-dihydro-1h-isoquinolin-6-amine Chemical compound NC1=CC=C2CN(C)CCC2=C1 PWHRVVMNFQGSJQ-UHFFFAOYSA-N 0.000 description 4
- VRKLIVSHUQSRNF-UHFFFAOYSA-N 2-methyl-3,4-dihydro-1h-isoquinolin-7-amine Chemical compound C1=C(N)C=C2CN(C)CCC2=C1 VRKLIVSHUQSRNF-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- 206010000830 Acute leukaemia Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 4
- 150000007942 carboxylates Chemical class 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
- 238000004737 colorimetric analysis Methods 0.000 description 4
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 229910052718 tin Inorganic materials 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 3
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[[(2R,4S,5S,6S)-4-amino-6-methyl-5-[[(2R)-2-oxanyl]oxy]-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 3
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 3
- UOFRTYMUEXDKJB-UHFFFAOYSA-N 13-hydroxy-6-methylsulfanyl-17-pyridin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11(16),12,14-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC(O)=CC=C1N3C1=CC=CC=N1 UOFRTYMUEXDKJB-UHFFFAOYSA-N 0.000 description 3
- PGZKBDPBVHGQAC-UHFFFAOYSA-N 17-(furan-3-yl)-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C=1C=COC=1 PGZKBDPBVHGQAC-UHFFFAOYSA-N 0.000 description 3
- LBDJZLDUCJTWJQ-UHFFFAOYSA-N 17-ethyl-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound CSC1=NC=C2C(=O)N3N(CC)C4=CC=CC=C4C3=NC2=N1 LBDJZLDUCJTWJQ-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- PLZYGXRMUHARPA-UHFFFAOYSA-N 2-fluoro-4-[(4-methoxyphenyl)methoxy]benzonitrile Chemical compound C1=CC(OC)=CC=C1COC1=CC=C(C#N)C(F)=C1 PLZYGXRMUHARPA-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 3
- WFPMWFUBUBIBOX-UHFFFAOYSA-N 4-methyl-n-phenylpiperazin-1-amine Chemical compound C1CN(C)CCN1NC1=CC=CC=C1 WFPMWFUBUBIBOX-UHFFFAOYSA-N 0.000 description 3
- CEDTZVIHIUIOFX-UHFFFAOYSA-N 5-[(4-methoxyphenyl)methoxy]-1h-indazol-3-amine Chemical compound C1=CC(OC)=CC=C1COC1=CC=C(NN=C2N)C2=C1 CEDTZVIHIUIOFX-UHFFFAOYSA-N 0.000 description 3
- KWPMCJYWTMFROE-UHFFFAOYSA-N 6-methylsulfanyl-17-(1,3-thiazol-4-yl)-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CSC=N1 KWPMCJYWTMFROE-UHFFFAOYSA-N 0.000 description 3
- IOGIBSFPAAAXQC-UHFFFAOYSA-N 6-methylsulfanyl-17-pyrazin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CN=CC=N1 IOGIBSFPAAAXQC-UHFFFAOYSA-N 0.000 description 3
- CQKRYIYWHCJFDL-UHFFFAOYSA-N 6-methylsulfanyl-17-pyridin-3-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC=CN=C1 CQKRYIYWHCJFDL-UHFFFAOYSA-N 0.000 description 3
- DASOJERUHVKKRT-UHFFFAOYSA-N 6-methylsulfanyl-17-pyridin-4-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC=NC=C1 DASOJERUHVKKRT-UHFFFAOYSA-N 0.000 description 3
- QIRHHJFDMMTBEI-UHFFFAOYSA-N 6-methylsulfanyl-17-pyrimidin-5-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CN=CN=C1 QIRHHJFDMMTBEI-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010004593 Bile duct cancer Diseases 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000006332 Choriocarcinoma Diseases 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- IBHPDYUCBBERQS-UHFFFAOYSA-N N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=C(O)C=CC=C1N3C1=CC=CC=N1 Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=C(O)C=CC=C1N3C1=CC=CC=N1 IBHPDYUCBBERQS-UHFFFAOYSA-N 0.000 description 3
- RYXUTVCQZYJREZ-UHFFFAOYSA-N N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=C(O)C=C1N3C1=CC=CC=N1 Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=C(O)C=C1N3C1=CC=CC=N1 RYXUTVCQZYJREZ-UHFFFAOYSA-N 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000002471 Penile Neoplasms Diseases 0.000 description 3
- 206010034299 Penile cancer Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 description 3
- 206010057644 Testis cancer Diseases 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 3
- 206010046392 Ureteric cancer Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 208000008383 Wilms tumor Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 208000026900 bile duct neoplasm Diseases 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000008004 cell lysis buffer Substances 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 201000010175 gallbladder cancer Diseases 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 210000000244 kidney pelvis Anatomy 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 201000008026 nephroblastoma Diseases 0.000 description 3
- 229950006344 nocodazole Drugs 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 201000003120 testicular cancer Diseases 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 3
- 201000011294 ureter cancer Diseases 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 2
- PZKULAVSWRTKAA-UHFFFAOYSA-N 1-(furan-3-yl)indazol-3-amine Chemical compound C12=CC=CC=C2C(N)=NN1C=1C=COC=1 PZKULAVSWRTKAA-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- JDXFAUMXVDRFMR-UHFFFAOYSA-N 1-cyclopropylindazol-3-amine Chemical compound C12=CC=CC=C2C(N)=NN1C1CC1 JDXFAUMXVDRFMR-UHFFFAOYSA-N 0.000 description 2
- 125000006017 1-propenyl group Chemical group 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- ZVCGXTNTCMZYIW-UHFFFAOYSA-N 14-fluoro-6-methylsulfanyl-17-pyridin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11(16),12,14-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=C(F)C=C1N3C1=CC=CC=N1 ZVCGXTNTCMZYIW-UHFFFAOYSA-N 0.000 description 2
- VWFICKBSSSTXKU-UHFFFAOYSA-N 17-(2,2-difluoroethyl)-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C12=CC=CC=C2N(CC(F)F)N2C1=NC1=NC(SC)=NC=C1C2=O VWFICKBSSSTXKU-UHFFFAOYSA-N 0.000 description 2
- ABXJZNDNGZJVMM-UHFFFAOYSA-N 17-(2-methoxyethyl)-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound CSC1=NC=C2C(=O)N3N(CCOC)C4=CC=CC=C4C3=NC2=N1 ABXJZNDNGZJVMM-UHFFFAOYSA-N 0.000 description 2
- IKDWGEIACWAZJL-UHFFFAOYSA-N 17-(3-methylpyridin-2-yl)-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CC=C1C IKDWGEIACWAZJL-UHFFFAOYSA-N 0.000 description 2
- OXBCLWIVJXFGDY-UHFFFAOYSA-N 17-(4-methylpyridin-2-yl)-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC(C)=CC=N1 OXBCLWIVJXFGDY-UHFFFAOYSA-N 0.000 description 2
- QJMBIKOCSGGUIP-UHFFFAOYSA-N 17-(5-methylpyridin-2-yl)-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC=C(C)C=N1 QJMBIKOCSGGUIP-UHFFFAOYSA-N 0.000 description 2
- YDLAWRRWULFNLK-UHFFFAOYSA-N 17-(6-methoxypyridin-2-yl)-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound COC1=CC=CC(N2N3C(=O)C4=CN=C(SC)N=C4N=C3C3=CC=CC=C32)=N1 YDLAWRRWULFNLK-UHFFFAOYSA-N 0.000 description 2
- MKUYYENXWSHANT-UHFFFAOYSA-N 17-(6-methylpyridin-2-yl)-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC=CC(C)=N1 MKUYYENXWSHANT-UHFFFAOYSA-N 0.000 description 2
- DTJRVHLFNZEKEU-UHFFFAOYSA-N 17-(cyclopropylmethyl)-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3CC1CC1 DTJRVHLFNZEKEU-UHFFFAOYSA-N 0.000 description 2
- PQJWSEXGDDFPNM-UHFFFAOYSA-N 17-[4-(hydroxymethyl)phenyl]-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC=C(CO)C=C1 PQJWSEXGDDFPNM-UHFFFAOYSA-N 0.000 description 2
- PNAMMKSTEYHJHC-UHFFFAOYSA-N 17-cyclopropyl-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1CC1 PNAMMKSTEYHJHC-UHFFFAOYSA-N 0.000 description 2
- YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical compound C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 2
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 2
- IYLCHYWVRNNZEB-UHFFFAOYSA-N 2-(6-methylsulfanyl-2-oxo-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-17-yl)propanenitrile Chemical compound C12=CC=CC=C2N(C(C)C#N)N2C1=NC1=NC(SC)=NC=C1C2=O IYLCHYWVRNNZEB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- UYPMJWFZFLMAPE-UHFFFAOYSA-N 2-fluoro-6-[(4-methoxyphenyl)methoxy]benzonitrile Chemical compound C1=CC(OC)=CC=C1COC1=CC=CC(F)=C1C#N UYPMJWFZFLMAPE-UHFFFAOYSA-N 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- BIJIAHGQTQWGJB-UHFFFAOYSA-N 2-methylsulfanylpyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C=N1 BIJIAHGQTQWGJB-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- OMANCHZBBJVYEJ-UHFFFAOYSA-N 4-(4-aminophenyl)-n,n,1-trimethylpiperazine-2-carboxamide Chemical compound C1CN(C)C(C(=O)N(C)C)CN1C1=CC=C(N)C=C1 OMANCHZBBJVYEJ-UHFFFAOYSA-N 0.000 description 2
- WSXURIGDIBZCHH-UHFFFAOYSA-N 4-(4-cyclopropylpiperazin-1-yl)-3-methylaniline Chemical compound CC1=CC(N)=CC=C1N1CCN(C2CC2)CC1 WSXURIGDIBZCHH-UHFFFAOYSA-N 0.000 description 2
- CRLKNBUQRZOYSE-UHFFFAOYSA-N 4-(4-propan-2-ylpiperazin-1-yl)aniline Chemical compound C1CN(C(C)C)CCN1C1=CC=C(N)C=C1 CRLKNBUQRZOYSE-UHFFFAOYSA-N 0.000 description 2
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 2
- OCGBBJFKEQEASN-SNVBAGLBSA-N 4-[(3r)-3,4-dimethylpiperazin-1-yl]aniline Chemical compound C1CN(C)[C@H](C)CN1C1=CC=C(N)C=C1 OCGBBJFKEQEASN-SNVBAGLBSA-N 0.000 description 2
- SBJQGGLWMJVETE-UHFFFAOYSA-N 4-[(4-methoxyphenyl)methoxy]-1h-indazol-3-amine Chemical compound C1=CC(OC)=CC=C1COC1=CC=CC2=C1C(N)=NN2 SBJQGGLWMJVETE-UHFFFAOYSA-N 0.000 description 2
- YUCLVOQRPCWJHW-UHFFFAOYSA-N 4-[(6-fluoro-1-pyridin-2-ylindazol-3-yl)amino]-2-methylsulfanylpyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C(NC=2C3=CC=C(F)C=C3N(C=3N=CC=CC=3)N=2)=N1 YUCLVOQRPCWJHW-UHFFFAOYSA-N 0.000 description 2
- NNCCQALFJIMRKB-UHFFFAOYSA-N 4-[(dimethylamino)methyl]aniline Chemical compound CN(C)CC1=CC=C(N)C=C1 NNCCQALFJIMRKB-UHFFFAOYSA-N 0.000 description 2
- AWKRZMJZGTVTPH-UHFFFAOYSA-N 4-[[1-(1-methylimidazol-2-yl)indazol-3-yl]amino]-2-methylsulfanylpyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C(NC=2C3=CC=CC=C3N(C=3N(C=CN=3)C)N=2)=N1 AWKRZMJZGTVTPH-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- ZDWSUNTYTPIPFH-UHFFFAOYSA-N 6-[(4-methoxyphenyl)methoxy]-1h-indazol-3-amine Chemical compound C1=CC(OC)=CC=C1COC1=CC=C(C(N)=NN2)C2=C1 ZDWSUNTYTPIPFH-UHFFFAOYSA-N 0.000 description 2
- BUJJVYGMDGXQAE-UHFFFAOYSA-N 6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C12=CC=CC=C2NN2C1=NC1=NC(SC)=NC=C1C2=O BUJJVYGMDGXQAE-UHFFFAOYSA-N 0.000 description 2
- DZVCOMITFJZVJR-UHFFFAOYSA-N 6-methylsulfanyl-17-(6-nitropyridin-2-yl)-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC=CC([N+]([O-])=O)=N1 DZVCOMITFJZVJR-UHFFFAOYSA-N 0.000 description 2
- YGEVRTZLEJQAPL-UHFFFAOYSA-N 6-methylsulfanyl-17-propyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound CSC1=NC=C2C(=O)N3N(CCC)C4=CC=CC=C4C3=NC2=N1 YGEVRTZLEJQAPL-UHFFFAOYSA-N 0.000 description 2
- AALBXPZCZINZKK-UHFFFAOYSA-N 6-methylsulfanyl-17-thiophen-3-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C=1C=CSC=1 AALBXPZCZINZKK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 230000010337 G2 phase Effects 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 108010066702 Thyrotropin Alfa Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 2
- 125000005103 alkyl silyl group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ASQQEOXYFGEFKQ-UHFFFAOYSA-N dioxirane Chemical compound C1OO1 ASQQEOXYFGEFKQ-UHFFFAOYSA-N 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- SNNHLSHDDGJVDM-UHFFFAOYSA-N ethyl 4-chloro-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1Cl SNNHLSHDDGJVDM-UHFFFAOYSA-N 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 2
- 229960000255 exemestane Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229940050176 methyl chloride Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000002902 organometallic compounds Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical compound OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- HZSBSRAVNBUZRA-RQDPQJJXSA-J (1r,2r)-cyclohexane-1,2-diamine;tetrachloroplatinum(2+) Chemical compound Cl[Pt+2](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N HZSBSRAVNBUZRA-RQDPQJJXSA-J 0.000 description 1
- PZJDWCYGPDQBKO-GFCCVEGCSA-N (3r)-1-(4-aminophenyl)-n,n-dimethylpyrrolidin-3-amine Chemical compound C1[C@H](N(C)C)CCN1C1=CC=C(N)C=C1 PZJDWCYGPDQBKO-GFCCVEGCSA-N 0.000 description 1
- PZJDWCYGPDQBKO-LBPRGKRZSA-N (3s)-1-(4-aminophenyl)-n,n-dimethylpyrrolidin-3-amine Chemical compound C1[C@@H](N(C)C)CCN1C1=CC=C(N)C=C1 PZJDWCYGPDQBKO-LBPRGKRZSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- OCWZIFDXNYNTPZ-UHFFFAOYSA-N (4-aminophenyl)-(1-methylpiperidin-4-yl)methanol Chemical compound C1CN(C)CCC1C(O)C1=CC=C(N)C=C1 OCWZIFDXNYNTPZ-UHFFFAOYSA-N 0.000 description 1
- WLQGXFSBIGJXDA-UHFFFAOYSA-N (4-bromo-1,3-thiazol-2-yl)-trimethylsilane Chemical compound C[Si](C)(C)C1=NC(Br)=CS1 WLQGXFSBIGJXDA-UHFFFAOYSA-N 0.000 description 1
- VUCXPUVUVWCVDL-UHFFFAOYSA-N (5-amino-2-morpholin-4-ylphenyl)methanol Chemical compound OCC1=CC(N)=CC=C1N1CCOCC1 VUCXPUVUVWCVDL-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- PQQASDABPMOHTI-UHFFFAOYSA-N 1,1,2-trimethyl-3,4-dihydroisoquinolin-6-amine Chemical compound NC1=CC=C2C(C)(C)N(C)CCC2=C1 PQQASDABPMOHTI-UHFFFAOYSA-N 0.000 description 1
- SAAFIVJVSQVSSW-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-6-amine Chemical compound C1NCCC2=CC(N)=CC=C21 SAAFIVJVSQVSSW-UHFFFAOYSA-N 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- LQRRWUKPTVQOHA-UHFFFAOYSA-N 1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-2,4,6,8,10,12,14,16-octaene Chemical group C1=NC=NC2=NC3=C4C=CC=CC4=NN3C=C21 LQRRWUKPTVQOHA-UHFFFAOYSA-N 0.000 description 1
- KCDYVWBFIBOQDU-UHFFFAOYSA-N 1-(1-methylimidazol-2-yl)indazol-3-amine Chemical compound CN1C=CN=C1N1C2=CC=CC=C2C(N)=N1 KCDYVWBFIBOQDU-UHFFFAOYSA-N 0.000 description 1
- XSXZKGLWPRJOMM-UHFFFAOYSA-N 1-(1-methylpiperidin-4-yl)pyrazol-4-amine Chemical compound C1CN(C)CCC1N1N=CC(N)=C1 XSXZKGLWPRJOMM-UHFFFAOYSA-N 0.000 description 1
- VKDVFUSENKSPEY-UHFFFAOYSA-N 1-(2-pyrrolidin-1-ylethyl)indol-5-amine Chemical compound C1=CC2=CC(N)=CC=C2N1CCN1CCCC1 VKDVFUSENKSPEY-UHFFFAOYSA-N 0.000 description 1
- NUOMYIPHFZUPIF-UHFFFAOYSA-N 1-(4-amino-2-fluorophenyl)-n,n-dimethylpyrrolidin-3-amine Chemical compound C1C(N(C)C)CCN1C1=CC=C(N)C=C1F NUOMYIPHFZUPIF-UHFFFAOYSA-N 0.000 description 1
- SINBMLKKTBWFQY-UHFFFAOYSA-N 1-(4-amino-2-methylphenyl)azetidin-3-ol Chemical compound CC1=CC(N)=CC=C1N1CC(O)C1 SINBMLKKTBWFQY-UHFFFAOYSA-N 0.000 description 1
- DJVKAFVFLKBXKO-UHFFFAOYSA-N 1-(4-amino-2-methylphenyl)piperidin-4-ol Chemical compound CC1=CC(N)=CC=C1N1CCC(O)CC1 DJVKAFVFLKBXKO-UHFFFAOYSA-N 0.000 description 1
- BOYVZXJHUROLHZ-UHFFFAOYSA-N 1-(4-aminophenoxy)-3-(dimethylamino)propan-2-ol Chemical compound CN(C)CC(O)COC1=CC=C(N)C=C1 BOYVZXJHUROLHZ-UHFFFAOYSA-N 0.000 description 1
- XSJRZKXWZPUVMZ-UHFFFAOYSA-N 1-(4-aminophenyl)-3-(dimethylamino)propan-1-ol Chemical compound CN(C)CCC(O)C1=CC=C(N)C=C1 XSJRZKXWZPUVMZ-UHFFFAOYSA-N 0.000 description 1
- KWUPUOUCMVGTON-UHFFFAOYSA-N 1-(4-aminophenyl)-4-methyl-1,4-diazepan-5-one Chemical compound C1CC(=O)N(C)CCN1C1=CC=C(N)C=C1 KWUPUOUCMVGTON-UHFFFAOYSA-N 0.000 description 1
- GPMQKWXGPNVWPB-UHFFFAOYSA-N 1-(4-aminophenyl)-n,n-dimethylazetidin-3-amine Chemical compound C1C(N(C)C)CN1C1=CC=C(N)C=C1 GPMQKWXGPNVWPB-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- YOUQFGVYWUQFDX-UHFFFAOYSA-N 1-[(4-aminophenyl)methyl]pyrrolidin-3-ol Chemical compound C1=CC(N)=CC=C1CN1CC(O)CC1 YOUQFGVYWUQFDX-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- CMUJYCZVTCSEPM-UHFFFAOYSA-N 1-[2-(dimethylamino)ethyl]-2,3-dihydroindol-5-amine Chemical compound NC1=CC=C2N(CCN(C)C)CCC2=C1 CMUJYCZVTCSEPM-UHFFFAOYSA-N 0.000 description 1
- ICUAGVJSPXSOIN-UHFFFAOYSA-N 1-[2-(dimethylamino)ethyl]indol-5-amine Chemical compound NC1=CC=C2N(CCN(C)C)C=CC2=C1 ICUAGVJSPXSOIN-UHFFFAOYSA-N 0.000 description 1
- PGXZHBBJSLVDIC-UHFFFAOYSA-N 1-[4-(4-amino-2-chlorophenyl)piperazin-1-yl]-2-methoxyethanone Chemical compound C1CN(C(=O)COC)CCN1C1=CC=C(N)C=C1Cl PGXZHBBJSLVDIC-UHFFFAOYSA-N 0.000 description 1
- IPTLIMLIOQMFKT-UHFFFAOYSA-N 1-[4-(4-amino-2-fluorophenyl)piperazin-1-yl]-2-methoxyethanone Chemical compound C1CN(C(=O)COC)CCN1C1=CC=C(N)C=C1F IPTLIMLIOQMFKT-UHFFFAOYSA-N 0.000 description 1
- LNSGXRMPNGIVIK-UHFFFAOYSA-N 1-[4-(4-amino-2-methylphenyl)piperazin-1-yl]-2-methoxyethanone Chemical compound C1CN(C(=O)COC)CCN1C1=CC=C(N)C=C1C LNSGXRMPNGIVIK-UHFFFAOYSA-N 0.000 description 1
- BTQJUUVJNALKTG-UHFFFAOYSA-N 1-[4-(4-amino-2-methylphenyl)piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(N)C=C1C BTQJUUVJNALKTG-UHFFFAOYSA-N 0.000 description 1
- AFVUJJNEILZYJQ-UHFFFAOYSA-N 1-[4-(4-aminophenyl)-1-piperazinyl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(N)C=C1 AFVUJJNEILZYJQ-UHFFFAOYSA-N 0.000 description 1
- HIJDBBJAGCPJJN-UHFFFAOYSA-N 1-[4-(4-aminophenyl)piperazin-1-yl]-2,2-dimethylpropan-1-one Chemical compound C1CN(C(=O)C(C)(C)C)CCN1C1=CC=C(N)C=C1 HIJDBBJAGCPJJN-UHFFFAOYSA-N 0.000 description 1
- UPGZLHQWLJVCLZ-UHFFFAOYSA-N 1-[4-(4-aminophenyl)piperazin-1-yl]-2-(dimethylamino)ethanone Chemical compound C1CN(C(=O)CN(C)C)CCN1C1=CC=C(N)C=C1 UPGZLHQWLJVCLZ-UHFFFAOYSA-N 0.000 description 1
- RNLOBBODGINRGF-UHFFFAOYSA-N 1-[4-(4-aminophenyl)piperazin-1-yl]-2-hydroxy-2-methylpropan-1-one Chemical compound C1CN(C(=O)C(C)(O)C)CCN1C1=CC=C(N)C=C1 RNLOBBODGINRGF-UHFFFAOYSA-N 0.000 description 1
- LNDCMYYVLUHCKN-UHFFFAOYSA-N 1-[4-(4-aminophenyl)piperazin-1-yl]-2-hydroxyethanone Chemical compound C1=CC(N)=CC=C1N1CCN(C(=O)CO)CC1 LNDCMYYVLUHCKN-UHFFFAOYSA-N 0.000 description 1
- WYNNHGYMGNNUFV-UHFFFAOYSA-N 1-[4-(4-aminophenyl)piperazin-1-yl]-2-methylpropan-1-one Chemical compound C1CN(C(=O)C(C)C)CCN1C1=CC=C(N)C=C1 WYNNHGYMGNNUFV-UHFFFAOYSA-N 0.000 description 1
- UUHPFZXZDIFXKR-UHFFFAOYSA-N 1-[4-[(4-aminophenyl)methyl]piperazin-1-yl]-2,2-dimethylpropan-1-one Chemical compound C1CN(C(=O)C(C)(C)C)CCN1CC1=CC=C(N)C=C1 UUHPFZXZDIFXKR-UHFFFAOYSA-N 0.000 description 1
- QDNQZSGOQYQWGV-UHFFFAOYSA-N 1-[4-[(4-aminophenyl)methyl]piperazin-1-yl]-2-methylpropan-1-one Chemical compound C1CN(C(=O)C(C)C)CCN1CC1=CC=C(N)C=C1 QDNQZSGOQYQWGV-UHFFFAOYSA-N 0.000 description 1
- NDQWVESCDAOZON-UHFFFAOYSA-N 1-[5-amino-2-(4-methylpiperazin-1-yl)phenyl]ethanol Chemical compound CC(O)C1=CC(N)=CC=C1N1CCN(C)CC1 NDQWVESCDAOZON-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- QGYITHAIIRZGQM-UHFFFAOYSA-N 1-cyclopropylindazole Chemical compound C1CC1N1C2=CC=CC=C2C=N1 QGYITHAIIRZGQM-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- CCQKLBKIVZTVQH-UHFFFAOYSA-N 1-ethylindazol-5-amine Chemical compound NC1=CC=C2N(CC)N=CC2=C1 CCQKLBKIVZTVQH-UHFFFAOYSA-N 0.000 description 1
- ODMRWSSWTARSNS-UHFFFAOYSA-N 1-ethylindazol-6-amine Chemical compound C1=C(N)C=C2N(CC)N=CC2=C1 ODMRWSSWTARSNS-UHFFFAOYSA-N 0.000 description 1
- IUYBQQPHRWZTTB-UHFFFAOYSA-N 1-ethylindol-5-amine Chemical compound NC1=CC=C2N(CC)C=CC2=C1 IUYBQQPHRWZTTB-UHFFFAOYSA-N 0.000 description 1
- 125000006019 1-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
- JRHPOFJADXHYBR-UHFFFAOYSA-N 1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CNC1CCCCC1NC JRHPOFJADXHYBR-UHFFFAOYSA-N 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- IGBQJDXVAKMCCB-UHFFFAOYSA-N 14-methoxy-6-methylsulfanyl-17-pyridin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11(16),12,14-heptaen-2-one Chemical compound C=1C(OC)=CC=C(C=2N3C(C4=CN=C(SC)N=C4N=2)=O)C=1N3C1=CC=CC=N1 IGBQJDXVAKMCCB-UHFFFAOYSA-N 0.000 description 1
- ALLDHVYWDVGZRF-UHFFFAOYSA-N 17-(1-methylimidazol-2-yl)-6-[4-(4-methylpiperazin-1-yl)anilino]-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N(C=CN=4)C)C4=CC=CC=C4C3=NC2=N1 ALLDHVYWDVGZRF-UHFFFAOYSA-N 0.000 description 1
- FYBZBFIJOBICFV-UHFFFAOYSA-N 17-(1-methylimidazol-2-yl)-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CN1C FYBZBFIJOBICFV-UHFFFAOYSA-N 0.000 description 1
- ORJUVCZSYXVYNE-UHFFFAOYSA-N 17-(3-hydroxypropyl)-6-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C1CN(C)CCN1C(C(=C1)C)=CC=C1NC1=NC=C2C(=O)N3N(CCCO)C4=CC=CC=C4C3=NC2=N1 ORJUVCZSYXVYNE-UHFFFAOYSA-N 0.000 description 1
- XEPWLZOANUXBSN-UHFFFAOYSA-N 17-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-6-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C1CN(C)CCN1C(C(=C1)C)=CC=C1NC1=NC=C2C(=O)N3N(CCO[Si](C)(C)C(C)(C)C)C4=CC=CC=C4C3=NC2=N1 XEPWLZOANUXBSN-UHFFFAOYSA-N 0.000 description 1
- RGBHWQXXAOTVIS-UHFFFAOYSA-N 17-[3-[tert-butyl(dimethyl)silyl]oxypropyl]-6-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C1CN(C)CCN1C(C(=C1)C)=CC=C1NC1=NC=C2C(=O)N3N(CCCO[Si](C)(C)C(C)(C)C)C4=CC=CC=C4C3=NC2=N1 RGBHWQXXAOTVIS-UHFFFAOYSA-N 0.000 description 1
- IWIWKKZVICXBNZ-UHFFFAOYSA-N 17-[6-(hydroxyamino)pyridin-2-yl]-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC=CC(NO)=N1 IWIWKKZVICXBNZ-UHFFFAOYSA-N 0.000 description 1
- VVKJDLBTGIVCKE-UHFFFAOYSA-N 17-benzyl-6-methylsulfanyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C(SC)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3CC1=CC=CC=C1 VVKJDLBTGIVCKE-UHFFFAOYSA-N 0.000 description 1
- ZPSKWVXODZTBEX-UHFFFAOYSA-N 17-cyclopropyl-6-[3-methyl-2-(4-methylpiperazin-1-yl)anilino]-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C1CN(C)CCN1C1=C(C)C=CC=C1NC1=NC=C2C(=O)N3N(C4CC4)C4=CC=CC=C4C3=NC2=N1 ZPSKWVXODZTBEX-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- RDAIEEVTJKDDQZ-UHFFFAOYSA-N 2,3-dihydroxypropyl phosphono hydrogen phosphate Chemical compound OCC(O)COP(O)(=O)OP(O)(O)=O RDAIEEVTJKDDQZ-UHFFFAOYSA-N 0.000 description 1
- BNBRIFIJRKJGEI-UHFFFAOYSA-N 2,6-difluorobenzonitrile Chemical compound FC1=CC=CC(F)=C1C#N BNBRIFIJRKJGEI-UHFFFAOYSA-N 0.000 description 1
- XXVBBTQFEBYHPR-UHFFFAOYSA-N 2-(1-cyclopropylindazol-3-yl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(C1=CC=CC=C11)=NN1C1CC1 XXVBBTQFEBYHPR-UHFFFAOYSA-N 0.000 description 1
- QZVLTKNDOHSWPC-UHFFFAOYSA-N 2-(1h-indazol-3-yl)isoindole-1,3-dione Chemical compound C1=CC=C2C(N3C(C4=CC=CC=C4C3=O)=O)=NNC2=C1 QZVLTKNDOHSWPC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- OZLADJXIVNANRO-UHFFFAOYSA-N 2-(7-amino-3,4-dihydro-1h-isoquinolin-2-yl)ethanol Chemical compound C1CN(CCO)CC2=CC(N)=CC=C21 OZLADJXIVNANRO-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- UDATZBUCZJXNIZ-UHFFFAOYSA-N 2-[1-(1-methylimidazol-2-yl)indazol-3-yl]isoindole-1,3-dione Chemical compound CN1C=CN=C1N1C2=CC=CC=C2C(N2C(C3=CC=CC=C3C2=O)=O)=N1 UDATZBUCZJXNIZ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CKIWSLHKXHTLPL-UHFFFAOYSA-N 2-[4-(4-amino-2-methylphenyl)piperazin-1-yl]ethanol Chemical compound CC1=CC(N)=CC=C1N1CCN(CCO)CC1 CKIWSLHKXHTLPL-UHFFFAOYSA-N 0.000 description 1
- HCDBHFCQLBZAAZ-UHFFFAOYSA-N 2-[4-(4-aminophenyl)piperazin-1-yl]ethanol Chemical compound C1=CC(N)=CC=C1N1CCN(CCO)CC1 HCDBHFCQLBZAAZ-UHFFFAOYSA-N 0.000 description 1
- JVYROUWXXSWCMI-UHFFFAOYSA-N 2-bromo-1,1-difluoroethane Chemical compound FC(F)CBr JVYROUWXXSWCMI-UHFFFAOYSA-N 0.000 description 1
- BANOTGHIHYMTDL-UHFFFAOYSA-N 2-bromo-1-methylimidazole Chemical compound CN1C=CN=C1Br BANOTGHIHYMTDL-UHFFFAOYSA-N 0.000 description 1
- LSZMVESSGLHDJE-UHFFFAOYSA-N 2-bromo-4-methylpyridine Chemical compound CC1=CC=NC(Br)=C1 LSZMVESSGLHDJE-UHFFFAOYSA-N 0.000 description 1
- YWNJQQNBJQUKME-UHFFFAOYSA-N 2-bromo-5-methylpyridine Chemical compound CC1=CC=C(Br)N=C1 YWNJQQNBJQUKME-UHFFFAOYSA-N 0.000 description 1
- KMODISUYWZPVGV-UHFFFAOYSA-N 2-bromo-6-methoxypyridine Chemical compound COC1=CC=CC(Br)=N1 KMODISUYWZPVGV-UHFFFAOYSA-N 0.000 description 1
- SOHDPICLICFSOP-UHFFFAOYSA-N 2-bromo-6-methylpyridine Chemical compound CC1=CC=CC(Br)=N1 SOHDPICLICFSOP-UHFFFAOYSA-N 0.000 description 1
- JULQLOHNPMMKTH-UHFFFAOYSA-N 2-bromo-6-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CC(Br)=N1 JULQLOHNPMMKTH-UHFFFAOYSA-N 0.000 description 1
- 125000006016 2-bromoethoxy group Chemical group 0.000 description 1
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 1
- PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 1
- 125000000872 2-diethylaminoethoxy group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- NADLTKBISYYXOX-UHFFFAOYSA-N 2-ethylindazol-5-amine Chemical compound C1=C(N)C=CC2=NN(CC)C=C21 NADLTKBISYYXOX-UHFFFAOYSA-N 0.000 description 1
- GHQLGRSPVIDMAX-UHFFFAOYSA-N 2-ethylindazol-6-amine Chemical compound C1=CC(N)=CC2=NN(CC)C=C21 GHQLGRSPVIDMAX-UHFFFAOYSA-N 0.000 description 1
- REIVHYDACHXPNH-UHFFFAOYSA-N 2-fluoro-4-hydroxybenzonitrile Chemical compound OC1=CC=C(C#N)C(F)=C1 REIVHYDACHXPNH-UHFFFAOYSA-N 0.000 description 1
- AJMBJGROMQSXCN-UHFFFAOYSA-N 2-fluoro-5-[(4-methoxyphenyl)methoxy]benzonitrile Chemical compound C1=CC(OC)=CC=C1COC1=CC=C(F)C(C#N)=C1 AJMBJGROMQSXCN-UHFFFAOYSA-N 0.000 description 1
- OYWPFIUVDKHHGQ-UHFFFAOYSA-N 2-iodopyrazine Chemical compound IC1=CN=CC=N1 OYWPFIUVDKHHGQ-UHFFFAOYSA-N 0.000 description 1
- HAKSOJQPTCMTAG-UHFFFAOYSA-N 2-methyl-1,3,4,5-tetrahydro-2-benzazepin-7-amine Chemical compound C1N(C)CCCC2=CC(N)=CC=C21 HAKSOJQPTCMTAG-UHFFFAOYSA-N 0.000 description 1
- QAJAXOPOSLBUDC-UHFFFAOYSA-N 2-methyl-1,3-dihydroisoindol-5-amine Chemical compound C1=C(N)C=C2CN(C)CC2=C1 QAJAXOPOSLBUDC-UHFFFAOYSA-N 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- RCWUBSWWRPUYDM-UHFFFAOYSA-N 2-methylsulfanyl-4-[(1-pyrazin-2-ylindazol-3-yl)amino]pyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C(NC=2C3=CC=CC=C3N(C=3N=CC=NC=3)N=2)=N1 RCWUBSWWRPUYDM-UHFFFAOYSA-N 0.000 description 1
- DBUJNOUEOGFVNE-UHFFFAOYSA-N 2-methylsulfanyl-4-[(1-pyridin-3-ylindazol-3-yl)amino]pyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C(NC=2C3=CC=CC=C3N(C=3C=NC=CC=3)N=2)=N1 DBUJNOUEOGFVNE-UHFFFAOYSA-N 0.000 description 1
- VALNZURTKUIFKE-UHFFFAOYSA-N 2-methylsulfanyl-4-[(1-pyridin-4-ylindazol-3-yl)amino]pyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C(NC=2C3=CC=CC=C3N(C=3C=CN=CC=3)N=2)=N1 VALNZURTKUIFKE-UHFFFAOYSA-N 0.000 description 1
- ICLVOPHQTIQSRN-UHFFFAOYSA-N 2-methylsulfanyl-4-[(1-pyrimidin-2-ylindazol-3-yl)amino]pyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C(NC=2C3=CC=CC=C3N(C=3N=CC=CN=3)N=2)=N1 ICLVOPHQTIQSRN-UHFFFAOYSA-N 0.000 description 1
- HZYZKXHZOIXFHN-UHFFFAOYSA-N 2-methylsulfanyl-4-[(1-pyrimidin-5-ylindazol-3-yl)amino]pyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C(NC=2C3=CC=CC=C3N(C=3C=NC=NC=3)N=2)=N1 HZYZKXHZOIXFHN-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- UWXHSQLUJJUUMI-UHFFFAOYSA-N 3-[3-(dimethylamino)propoxy]-4-methoxyaniline Chemical compound COC1=CC=C(N)C=C1OCCCN(C)C UWXHSQLUJJUUMI-UHFFFAOYSA-N 0.000 description 1
- DZHJIPSTTUJEGX-UHFFFAOYSA-N 3-[3-(dimethylamino)propoxy]-4-methylaniline Chemical compound CN(C)CCCOC1=CC(N)=CC=C1C DZHJIPSTTUJEGX-UHFFFAOYSA-N 0.000 description 1
- HYNCMEQKRXCLEF-UHFFFAOYSA-N 3-[3-(dimethylamino)propoxy]aniline Chemical compound CN(C)CCCOC1=CC=CC(N)=C1 HYNCMEQKRXCLEF-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ARVAJFOYUNZGNL-UHFFFAOYSA-N 3-bromo-2-methylpropanenitrile Chemical compound BrCC(C)C#N ARVAJFOYUNZGNL-UHFFFAOYSA-N 0.000 description 1
- LXWLEQZDXOQZGW-UHFFFAOYSA-N 3-bromofuran Chemical compound BrC=1C=COC=1 LXWLEQZDXOQZGW-UHFFFAOYSA-N 0.000 description 1
- QGMROEZDWJTIDW-UHFFFAOYSA-N 3-bromopropoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCBr QGMROEZDWJTIDW-UHFFFAOYSA-N 0.000 description 1
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-M 3-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-M 0.000 description 1
- GOPUCAPKOUZKPS-UHFFFAOYSA-N 3-fluoro-4-(4-methylpiperazin-1-yl)aniline Chemical compound C1CN(C)CCN1C1=CC=C(N)C=C1F GOPUCAPKOUZKPS-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- AFEAGBCLWMVRHF-UHFFFAOYSA-N 3-methoxy-4-(4-methylpiperazin-1-yl)aniline Chemical compound COC1=CC(N)=CC=C1N1CCN(C)CC1 AFEAGBCLWMVRHF-UHFFFAOYSA-N 0.000 description 1
- YJVJSCBQESKRQM-UHFFFAOYSA-N 3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-amine Chemical compound C1CN(C)CCC2=CC=C(N)C=C21 YJVJSCBQESKRQM-UHFFFAOYSA-N 0.000 description 1
- YWSMNNZYZSCMOO-UHFFFAOYSA-N 4-(1,4-dimethylpiperidin-4-yl)aniline Chemical compound C1CN(C)CCC1(C)C1=CC=C(N)C=C1 YWSMNNZYZSCMOO-UHFFFAOYSA-N 0.000 description 1
- BNYVBWBKNDWCQW-UHFFFAOYSA-N 4-(1-methylpiperidin-4-yl)aniline Chemical compound C1CN(C)CCC1C1=CC=C(N)C=C1 BNYVBWBKNDWCQW-UHFFFAOYSA-N 0.000 description 1
- CIVRCZPEYZHQDI-UHFFFAOYSA-N 4-(1-methylpiperidin-4-yl)oxyaniline Chemical compound C1CN(C)CCC1OC1=CC=C(N)C=C1 CIVRCZPEYZHQDI-UHFFFAOYSA-N 0.000 description 1
- ICTGXNILNPWNLH-UHFFFAOYSA-N 4-(1-methylpyrrolidin-3-yl)oxyaniline Chemical compound C1N(C)CCC1OC1=CC=C(N)C=C1 ICTGXNILNPWNLH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UYTPFLNIHHPILH-UHFFFAOYSA-N 4-(4-amino-2-methylphenyl)-n,n,1-trimethylpiperazine-2-carboxamide Chemical compound C1CN(C)C(C(=O)N(C)C)CN1C1=CC=C(N)C=C1C UYTPFLNIHHPILH-UHFFFAOYSA-N 0.000 description 1
- FMLOSYIZNDLWOM-UHFFFAOYSA-N 4-(4-methyl-1,4-diazepan-1-yl)aniline Chemical compound C1CN(C)CCCN1C1=CC=C(N)C=C1 FMLOSYIZNDLWOM-UHFFFAOYSA-N 0.000 description 1
- JCEIQYAKMMYTMD-UHFFFAOYSA-N 4-(4-methylpiperazin-2-yl)aniline Chemical compound C1N(C)CCNC1C1=CC=C(N)C=C1 JCEIQYAKMMYTMD-UHFFFAOYSA-N 0.000 description 1
- XEYAFBDCGVTSKX-SNVBAGLBSA-N 4-[(2r)-2,4-dimethylpiperazin-1-yl]aniline Chemical compound C[C@@H]1CN(C)CCN1C1=CC=C(N)C=C1 XEYAFBDCGVTSKX-SNVBAGLBSA-N 0.000 description 1
- KHSIXMJGWREPPT-CYBMUJFWSA-N 4-[(2r)-2-(methoxymethyl)-4-methylpiperazin-2-yl]aniline Chemical compound C=1C=C(N)C=CC=1[C@]1(COC)CN(C)CCN1 KHSIXMJGWREPPT-CYBMUJFWSA-N 0.000 description 1
- XEYAFBDCGVTSKX-JTQLQIEISA-N 4-[(2s)-2,4-dimethylpiperazin-1-yl]aniline Chemical compound C[C@H]1CN(C)CCN1C1=CC=C(N)C=C1 XEYAFBDCGVTSKX-JTQLQIEISA-N 0.000 description 1
- WASIAYSMRAPPCE-AWEZNQCLSA-N 4-[(3r)-4-methyl-3-propan-2-ylpiperazin-1-yl]aniline Chemical compound C1CN(C)[C@H](C(C)C)CN1C1=CC=C(N)C=C1 WASIAYSMRAPPCE-AWEZNQCLSA-N 0.000 description 1
- OCGBBJFKEQEASN-JTQLQIEISA-N 4-[(3s)-3,4-dimethylpiperazin-1-yl]aniline Chemical compound C1CN(C)[C@@H](C)CN1C1=CC=C(N)C=C1 OCGBBJFKEQEASN-JTQLQIEISA-N 0.000 description 1
- WASIAYSMRAPPCE-CQSZACIVSA-N 4-[(3s)-4-methyl-3-propan-2-ylpiperazin-1-yl]aniline Chemical compound C1CN(C)[C@@H](C(C)C)CN1C1=CC=C(N)C=C1 WASIAYSMRAPPCE-CQSZACIVSA-N 0.000 description 1
- NIXCVBFXLJWUTC-UHFFFAOYSA-N 4-[(4-methylpiperazin-1-yl)methyl]aniline Chemical compound C1CN(C)CCN1CC1=CC=C(N)C=C1 NIXCVBFXLJWUTC-UHFFFAOYSA-N 0.000 description 1
- TYSQKAQUDQOCKT-UHFFFAOYSA-N 4-[1-(dimethylamino)propan-2-yloxy]aniline Chemical compound CN(C)CC(C)OC1=CC=C(N)C=C1 TYSQKAQUDQOCKT-UHFFFAOYSA-N 0.000 description 1
- LFJGGGIWERIGNX-UHFFFAOYSA-N 4-[2-(diethylamino)ethoxy]aniline Chemical compound CCN(CC)CCOC1=CC=C(N)C=C1 LFJGGGIWERIGNX-UHFFFAOYSA-N 0.000 description 1
- RQZUMYLTTXQIQZ-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-3-methylaniline Chemical compound CN(C)CCOC1=CC=C(N)C=C1C RQZUMYLTTXQIQZ-UHFFFAOYSA-N 0.000 description 1
- CCCVQPGAXZNTIL-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]aniline Chemical compound CN(C)CCOC1=CC=C(N)C=C1 CCCVQPGAXZNTIL-UHFFFAOYSA-N 0.000 description 1
- XPKKPVBDOPPWJU-UHFFFAOYSA-N 4-[2-(dimethylamino)ethyl]aniline Chemical compound CN(C)CCC1=CC=C(N)C=C1 XPKKPVBDOPPWJU-UHFFFAOYSA-N 0.000 description 1
- ZIUOGXYQWQLNQL-UHFFFAOYSA-N 4-[2-(dimethylamino)propoxy]aniline Chemical compound CN(C)C(C)COC1=CC=C(N)C=C1 ZIUOGXYQWQLNQL-UHFFFAOYSA-N 0.000 description 1
- DQBHCFICRMRYKE-UHFFFAOYSA-N 4-[2-[methyl(propan-2-yl)amino]ethoxy]aniline Chemical compound CC(C)N(C)CCOC1=CC=C(N)C=C1 DQBHCFICRMRYKE-UHFFFAOYSA-N 0.000 description 1
- GKIBVBJBPWXECA-UHFFFAOYSA-N 4-[3-(dimethylamino)-2-methylpropoxy]aniline Chemical compound CN(C)CC(C)COC1=CC=C(N)C=C1 GKIBVBJBPWXECA-UHFFFAOYSA-N 0.000 description 1
- IADPSLNXAVFSSJ-UHFFFAOYSA-N 4-[3-(dimethylamino)propoxy]-3-methoxyaniline Chemical compound COC1=CC(N)=CC=C1OCCCN(C)C IADPSLNXAVFSSJ-UHFFFAOYSA-N 0.000 description 1
- MOXSUJYRRRCATL-UHFFFAOYSA-N 4-[3-(dimethylamino)propoxy]aniline Chemical compound CN(C)CCCOC1=CC=C(N)C=C1 MOXSUJYRRRCATL-UHFFFAOYSA-N 0.000 description 1
- GXMBOYZTJQUCGE-UHFFFAOYSA-N 4-[4-(2-methoxyethyl)piperazin-1-yl]-3-methylaniline Chemical compound C1CN(CCOC)CCN1C1=CC=C(N)C=C1C GXMBOYZTJQUCGE-UHFFFAOYSA-N 0.000 description 1
- RZHDUDHEYSWAMQ-UHFFFAOYSA-N 4-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]aniline Chemical compound O1C(CN(C)C)=NC(C=2C=CC(N)=CC=2)=N1 RZHDUDHEYSWAMQ-UHFFFAOYSA-N 0.000 description 1
- FDHVCLWIZLBSDM-UHFFFAOYSA-N 4-[[4-[(4-methoxyphenyl)methoxy]-1-pyridin-2-ylindazol-3-yl]amino]-2-methylsulfanylpyrimidine-5-carboxylic acid Chemical compound C1=CC(OC)=CC=C1COC1=CC=CC2=C1C(NC=1C(=CN=C(SC)N=1)C(O)=O)=NN2C1=CC=CC=N1 FDHVCLWIZLBSDM-UHFFFAOYSA-N 0.000 description 1
- IPPOXNQDJDTVMA-UHFFFAOYSA-N 4-[[5-[(4-methoxyphenyl)methoxy]-1-pyridin-2-ylindazol-3-yl]amino]-2-methylsulfanylpyrimidine-5-carboxylic acid Chemical compound C1=CC(OC)=CC=C1COC1=CC=C(N(N=C2NC=3C(=CN=C(SC)N=3)C(O)=O)C=3N=CC=CC=3)C2=C1 IPPOXNQDJDTVMA-UHFFFAOYSA-N 0.000 description 1
- BTEYKNJSAAQFHU-UHFFFAOYSA-N 4-[[6-[(4-methoxyphenyl)methoxy]-1-pyridin-2-ylindazol-3-yl]amino]-2-methylsulfanylpyrimidine-5-carboxylic acid Chemical compound C1=CC(OC)=CC=C1COC1=CC=C(C(NC=2C(=CN=C(SC)N=2)C(O)=O)=NN2C=3N=CC=CC=3)C2=C1 BTEYKNJSAAQFHU-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- BSDGZUDFPKIYQG-UHFFFAOYSA-N 4-bromopyridine Chemical compound BrC1=CC=NC=C1 BSDGZUDFPKIYQG-UHFFFAOYSA-N 0.000 description 1
- QNGVNLMMEQUVQK-UHFFFAOYSA-N 4-n,4-n-diethylbenzene-1,4-diamine Chemical compound CCN(CC)C1=CC=C(N)C=C1 QNGVNLMMEQUVQK-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- YWGMZWINPMWUGA-UHFFFAOYSA-N 5-amino-n,n-dimethyl-2-(4-methylpiperazin-1-yl)benzamide Chemical compound CN(C)C(=O)C1=CC(N)=CC=C1N1CCN(C)CC1 YWGMZWINPMWUGA-UHFFFAOYSA-N 0.000 description 1
- GYCPLYCTMDTEPU-UHFFFAOYSA-N 5-bromopyrimidine Chemical compound BrC1=CN=CN=C1 GYCPLYCTMDTEPU-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- SHFIMZAZXGRNPI-UHFFFAOYSA-N 6-(4-piperidin-2-ylanilino)-17-pyrimidin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N1=C2N=C3C4=CC=CC=C4N(C=4N=CC=CN=4)N3C(=O)C2=CN=C1NC(C=C1)=CC=C1C1CCCCN1 SHFIMZAZXGRNPI-UHFFFAOYSA-N 0.000 description 1
- XOPHYEQAZSHUKR-UHFFFAOYSA-N 6-[3-(hydroxymethyl)-4-(4-methylpiperazin-1-yl)anilino]-17-(1,3-thiazol-2-yl)-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C1CN(C)CCN1C(C(=C1)CO)=CC=C1NC1=NC=C2C(=O)N3N(C=4SC=CN=4)C4=CC=CC=C4C3=NC2=N1 XOPHYEQAZSHUKR-UHFFFAOYSA-N 0.000 description 1
- GUCQFNDTYIALLM-UHFFFAOYSA-N 6-[3-(hydroxymethyl)-4-morpholin-4-ylanilino]-17-methyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C=C2C(=O)N3N(C)C4=CC=CC=C4C3=NC2=NC=1NC(C=C1CO)=CC=C1N1CCOCC1 GUCQFNDTYIALLM-UHFFFAOYSA-N 0.000 description 1
- VBWYBXRVBBQFHK-UHFFFAOYSA-N 6-[4-(4-cyclopropylpiperazin-1-yl)-3-methylanilino]-17-pyridin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C=1C=C(N2CCN(CC2)C2CC2)C(C)=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=CC=CC=N1 VBWYBXRVBBQFHK-UHFFFAOYSA-N 0.000 description 1
- AEOCQFZGHQXYKL-GOSISDBHSA-N 6-[4-[(2R)-2,4-dimethylpiperazin-1-yl]anilino]-17-pyrimidin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C[C@@H]1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 AEOCQFZGHQXYKL-GOSISDBHSA-N 0.000 description 1
- AEOCQFZGHQXYKL-SFHVURJKSA-N 6-[4-[(2S)-2,4-dimethylpiperazin-1-yl]anilino]-17-pyrimidin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C[C@H]1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 AEOCQFZGHQXYKL-SFHVURJKSA-N 0.000 description 1
- MEZUVSTUCXUMDS-GOSISDBHSA-N 6-[4-[(3R)-3,4-dimethylpiperazin-1-yl]anilino]-17-pyrimidin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C1CN(C)[C@H](C)CN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 MEZUVSTUCXUMDS-GOSISDBHSA-N 0.000 description 1
- MEZUVSTUCXUMDS-SFHVURJKSA-N 6-[4-[(3S)-3,4-dimethylpiperazin-1-yl]anilino]-17-pyrimidin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C1CN(C)[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CN=4)C4=CC=CC=C4C3=NC2=N1 MEZUVSTUCXUMDS-SFHVURJKSA-N 0.000 description 1
- BZBYFQODBKACAO-UHFFFAOYSA-N 6-[4-[3-(hydroxymethyl)-4-methylpiperazin-1-yl]anilino]-17-(1,3-thiazol-2-yl)-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C1C(CO)N(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4SC=CN=4)C4=CC=CC=C4C3=NC2=N1 BZBYFQODBKACAO-UHFFFAOYSA-N 0.000 description 1
- ODIOJNHAXFHTEJ-UHFFFAOYSA-N 6-[4-[[4-(2-methylpropanoyl)piperazin-1-yl]methyl]anilino]-17-pyridin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C1CN(C(=O)C(C)C)CCN1CC(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C=4N=CC=CC=4)C4=CC=CC=C4C3=NC2=N1 ODIOJNHAXFHTEJ-UHFFFAOYSA-N 0.000 description 1
- ZVCVHZHVKVSSOQ-UHFFFAOYSA-N 6-[[1-[2-(dimethylamino)ethyl]indol-5-yl]amino]-17-pyrimidin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C=1C=C2N(CCN(C)C)C=CC2=CC=1NC(N=1)=NC=C(C(N23)=O)C=1N=C2C1=CC=CC=C1N3C1=NC=CC=N1 ZVCVHZHVKVSSOQ-UHFFFAOYSA-N 0.000 description 1
- PPUGIOAVTWGKFF-UHFFFAOYSA-N 6-anilino-17-methyl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N=1C=C2C(=O)N3N(C)C4=CC=CC=C4C3=NC2=NC=1NC1=CC=CC=C1 PPUGIOAVTWGKFF-UHFFFAOYSA-N 0.000 description 1
- TVTWJAJXRRLRKP-UHFFFAOYSA-N 6-anilino-17-pyridin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound N1=C2N=C3C4=CC=CC=C4N(C=4N=CC=CC=4)N3C(=O)C2=CN=C1NC1=CC=CC=C1 TVTWJAJXRRLRKP-UHFFFAOYSA-N 0.000 description 1
- QDSGPWDYMOHCFA-UHFFFAOYSA-N 6-bromo-n,n-dimethylpyridine-2-carboxamide Chemical compound CN(C)C(=O)C1=CC=CC(Br)=N1 QDSGPWDYMOHCFA-UHFFFAOYSA-N 0.000 description 1
- UUMFIOSLMPIDKB-UHFFFAOYSA-N 6-bromo-n,n-dimethylpyridine-3-carboxamide Chemical compound CN(C)C(=O)C1=CC=C(Br)N=C1 UUMFIOSLMPIDKB-UHFFFAOYSA-N 0.000 description 1
- JKOGFRGFWFEFNT-UHFFFAOYSA-N 6-fluoro-1h-indazol-3-amine Chemical compound FC1=CC=C2C(N)=NNC2=C1 JKOGFRGFWFEFNT-UHFFFAOYSA-N 0.000 description 1
- VPXRJPAUOYDKQY-UHFFFAOYSA-N 6-methylsulfanyl-17-propan-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one Chemical compound C12=CC=CC=C2N(C(C)C)N2C1=NC1=NC(SC)=NC=C1C2=O VPXRJPAUOYDKQY-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- QBFVPFYWGKMLTR-UHFFFAOYSA-N C1=CC(OCCN(C)C(C)C)=CC=C1NC1=NC=C2C(=O)N3N(C=4SC=CN=4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1=CC(OCCN(C)C(C)C)=CC=C1NC1=NC=C2C(=O)N3N(C=4SC=CN=4)C4=CC=CC=C4C3=NC2=N1 QBFVPFYWGKMLTR-UHFFFAOYSA-N 0.000 description 1
- JUZOKMYGVIPQPB-UHFFFAOYSA-N C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C4=COC=C4)C4=CC=CC=C4C3=NC2=N1 Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N3N(C4=COC=C4)C4=CC=CC=C4C3=NC2=N1 JUZOKMYGVIPQPB-UHFFFAOYSA-N 0.000 description 1
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- LQTADOFKKROUBD-UHFFFAOYSA-N FC1=C(C#N)C=CC(=C1)F.FC1=CC=C2C(=NNC2=C1)N Chemical compound FC1=C(C#N)C=CC(=C1)F.FC1=CC=C2C(=NNC2=C1)N LQTADOFKKROUBD-UHFFFAOYSA-N 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 244000300477 Gardenia carinata Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 244000146510 Pereskia bleo Species 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- XRKLKRCRKKGHRN-GFCCVEGCSA-N [(2r)-1-(4-aminophenyl)-4-methylpiperazin-2-yl]methanol Chemical compound OC[C@H]1CN(C)CCN1C1=CC=C(N)C=C1 XRKLKRCRKKGHRN-GFCCVEGCSA-N 0.000 description 1
- XRKLKRCRKKGHRN-LBPRGKRZSA-N [(2s)-1-(4-aminophenyl)-4-methylpiperazin-2-yl]methanol Chemical compound OC[C@@H]1CN(C)CCN1C1=CC=C(N)C=C1 XRKLKRCRKKGHRN-LBPRGKRZSA-N 0.000 description 1
- KMLCRELJHYKIIL-UHFFFAOYSA-N [1-(azanidylmethyl)cyclohexyl]methylazanide;platinum(2+);sulfuric acid Chemical compound [Pt+2].OS(O)(=O)=O.[NH-]CC1(C[NH-])CCCCC1 KMLCRELJHYKIIL-UHFFFAOYSA-N 0.000 description 1
- FVJBDYRBJRFNJT-UHFFFAOYSA-N [4-(4-aminophenyl)-1-methylpiperazin-2-yl]methanol Chemical compound C1C(CO)N(C)CCN1C1=CC=C(N)C=C1 FVJBDYRBJRFNJT-UHFFFAOYSA-N 0.000 description 1
- VBEUSNCGYDQVDW-UHFFFAOYSA-N [4-(4-aminophenyl)piperazin-1-yl]-cyclobutylmethanone Chemical compound C1=CC(N)=CC=C1N1CCN(C(=O)C2CCC2)CC1 VBEUSNCGYDQVDW-UHFFFAOYSA-N 0.000 description 1
- WTLKZCHODLBPMW-UHFFFAOYSA-N [4-(4-aminophenyl)piperazin-1-yl]-cyclopropylmethanone Chemical compound C1=CC(N)=CC=C1N1CCN(C(=O)C2CC2)CC1 WTLKZCHODLBPMW-UHFFFAOYSA-N 0.000 description 1
- PZRPBPMLSSNFOM-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=C(B(O)O)C=C1 PZRPBPMLSSNFOM-UHFFFAOYSA-N 0.000 description 1
- RJIWXFXUGNZHKX-UHFFFAOYSA-N [5-amino-2-(4-methylpiperazin-1-yl)phenyl]methanol Chemical compound C1CN(C)CCN1C1=CC=C(N)C=C1CO RJIWXFXUGNZHKX-UHFFFAOYSA-N 0.000 description 1
- VCRTYXDGVVHNTD-UHFFFAOYSA-J [Cu](I)I.FC(S(=O)(=O)[O-])(F)F.[Cu+2].FC(S(=O)(=O)[O-])(F)F Chemical compound [Cu](I)I.FC(S(=O)(=O)[O-])(F)F.[Cu+2].FC(S(=O)(=O)[O-])(F)F VCRTYXDGVVHNTD-UHFFFAOYSA-J 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940110282 alimta Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BSJGASKRWFKGMV-UHFFFAOYSA-L ammonia dichloroplatinum(2+) Chemical compound N.N.Cl[Pt+2]Cl BSJGASKRWFKGMV-UHFFFAOYSA-L 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 229940087620 aromasin Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- VWCPNTATQBOMGQ-UHFFFAOYSA-M bis(2-azanidylethyl)azanide;platinum(4+);chloride Chemical compound [Cl-].[Pt+4].[NH-]CC[N-]CC[NH-] VWCPNTATQBOMGQ-UHFFFAOYSA-M 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000006243 carbonyl protecting group Chemical group 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229940088547 cosmegen Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- SGLJYTWMWIAGEU-UHFFFAOYSA-N cyclohexane-1,2-diamine;platinum(2+) Chemical compound [Pt+2].NC1CCCCC1N SGLJYTWMWIAGEU-UHFFFAOYSA-N 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- XDRVAZAFNWDVOE-UHFFFAOYSA-N cyclohexylboronic acid Chemical compound OB(O)C1CCCCC1 XDRVAZAFNWDVOE-UHFFFAOYSA-N 0.000 description 1
- KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 229940120655 eloxatin Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- LMABILRJNNFCPG-UHFFFAOYSA-L ethane-1,2-diamine;platinum(2+);dichloride Chemical compound [Cl-].[Cl-].[Pt+2].NCCN LMABILRJNNFCPG-UHFFFAOYSA-L 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- YCWDQAKDVQNVAR-UHFFFAOYSA-N ethyl pyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=CN=C1 YCWDQAKDVQNVAR-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 229950009822 gimeracil Drugs 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229940096120 hydrea Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 229940099279 idamycin Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950010897 iproplatin Drugs 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229940050492 leucovorin 200 mg Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- LVLZILAEKZZEQY-UHFFFAOYSA-N methyl 4-(4-aminophenoxy)butanoate Chemical compound COC(=O)CCCOC1=CC=C(N)C=C1 LVLZILAEKZZEQY-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- IRQWCOFOSMREBQ-UHFFFAOYSA-N n,n-dimethylazetidin-3-amine Chemical compound CN(C)C1CNC1 IRQWCOFOSMREBQ-UHFFFAOYSA-N 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N n-[1-(2-carbamoylpyrrolidin-1-yl)-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940100027 ontak Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229950008017 ormaplatin Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- QJVSMHJWAOSBMD-MYXYZBIASA-L pemetrexed disodium heptahydrate Chemical group O.O.O.O.O.O.O.[Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 QJVSMHJWAOSBMD-MYXYZBIASA-L 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- BRYCUMKDWMEGMK-UHFFFAOYSA-N piperazine-2-carboxamide Chemical compound NC(=O)C1CNCCN1 BRYCUMKDWMEGMK-UHFFFAOYSA-N 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- DERJYEZSLHIUKF-UHFFFAOYSA-N procarbazine hydrochloride Chemical compound Cl.CNNCC1=CC=C(C(=O)NC(C)C)C=C1 DERJYEZSLHIUKF-UHFFFAOYSA-N 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- GFGFXJMTIXGYHF-UHFFFAOYSA-N pyrimido[1,2-b]indazole Chemical compound C1=CC=NC2=C3C=CC=CC3=NN21 GFGFXJMTIXGYHF-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229950004330 spiroplatin Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- USGKAXIJKNBDSV-UHFFFAOYSA-N tert-butyl 2-(4-aminophenyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1C1=CC=C(N)C=C1 USGKAXIJKNBDSV-UHFFFAOYSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960000902 thyrotropin alfa Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000016596 traversing start control point of mitotic cell cycle Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229940086984 trisenox Drugs 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011535742A JP2012518598A (ja) | 2009-02-25 | 2010-02-18 | ピリミドピリミドインダゾール誘導体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009042873 | 2009-02-25 | ||
| JP2009042873 | 2009-02-25 | ||
| PCT/JP2010/052910 WO2010098367A1 (en) | 2009-02-25 | 2010-02-18 | Pyrimidopyrimidoindazole derivative |
| JP2011535742A JP2012518598A (ja) | 2009-02-25 | 2010-02-18 | ピリミドピリミドインダゾール誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012518598A true JP2012518598A (ja) | 2012-08-16 |
| JP2012518598A5 JP2012518598A5 (OSRAM) | 2013-04-04 |
Family
ID=42665571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535742A Pending JP2012518598A (ja) | 2009-02-25 | 2010-02-18 | ピリミドピリミドインダゾール誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8288396B2 (OSRAM) |
| EP (1) | EP2401281A4 (OSRAM) |
| JP (1) | JP2012518598A (OSRAM) |
| AU (1) | AU2010218781A1 (OSRAM) |
| CA (1) | CA2750716A1 (OSRAM) |
| WO (1) | WO2010098367A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2017127088A (ru) | 2010-11-16 | 2019-02-04 | Эррэй Биофарма Инк. | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 |
| JP6313312B2 (ja) | 2012-10-02 | 2018-04-18 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 農薬としての複素環化合物 |
| FR3030513B1 (fr) * | 2014-12-19 | 2016-12-23 | Oreal | Derives de benzoxazine cationiques et utilisation en coloration capillaire. |
| DE102015012050A1 (de) * | 2015-09-15 | 2017-03-16 | Merck Patent Gmbh | Verbindungen als ASIC-Inhibitoren und deren Verwendungen |
| AU2018243667A1 (en) | 2017-03-31 | 2019-10-17 | Seagen Inc. | Combinations of Chk1- and Wee1 - inhibitors |
| AR111419A1 (es) | 2017-04-27 | 2019-07-10 | Novartis Ag | Compuestos fusionados de indazol piridona como antivirales |
| US11234977B2 (en) | 2017-12-20 | 2022-02-01 | Novartis Ag | Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals |
| CN109912606B (zh) * | 2019-04-16 | 2021-05-04 | 新乡医学院 | 一种嘧啶并吲唑类化合物的合成方法 |
| CA3145344A1 (en) | 2019-06-28 | 2020-12-30 | Shanghai Pharmaceuticals Holding Co., Ltd. | Pyrazolopyrimidine compound, preparation method for same and applications thereof |
| CN112142748B (zh) | 2019-06-28 | 2023-07-04 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002516327A (ja) * | 1998-05-26 | 2002-06-04 | ワーナー−ランバート・カンパニー | 細胞増殖の阻害剤としての二環式ピリミジンおよび二環式3,4−ジヒドロピリミジン |
| JP2006504632A (ja) * | 2002-04-26 | 2006-02-09 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | チェックポイントキナーゼ(Wee1およびChk1)の阻害剤 |
| WO2007126128A1 (ja) * | 2006-04-27 | 2007-11-08 | Banyu Pharmaceutical Co., Ltd. | ジヒドロピラゾロピリミジノン誘導体 |
| WO2008153207A1 (ja) * | 2007-06-15 | 2008-12-18 | Banyu Pharmaceutical Co., Ltd | ビシクロアニリン誘導体 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US5223608A (en) | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| ATE186461T1 (de) | 1990-09-28 | 1999-11-15 | Smithkline Beecham Corp | Verfahren zur herstellung wasserlöslicher camptothecinanaloge, sowie die verbindungen 10- hydroxy-11-c(1-6)-alkoxycamptothecin |
| US5162532A (en) | 1990-12-20 | 1992-11-10 | North Carolina State University | Intermediates and method of making camptothecin and camptothecin analogs |
| US5243050A (en) | 1990-12-20 | 1993-09-07 | North Carolina State University | Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US5200524A (en) | 1990-12-20 | 1993-04-06 | North Carolina State University | Camptothecin intermediates and method of making same |
| US5191082A (en) | 1990-12-20 | 1993-03-02 | North Carolina State University | Camptothecin intermediate and method of making camptothecin intermediates |
| US5247089A (en) | 1990-12-20 | 1993-09-21 | North Carolina State University | Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
| JP3025602B2 (ja) | 1993-05-21 | 2000-03-27 | デビオファーム エス.アー. | 光学的に高純度なシス−オキザラート(トランス−l−1,2−シクロヘキサンジアミン)白金(II)錯体の製造方法 |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
| JP3154399B2 (ja) | 1996-07-04 | 2001-04-09 | デビオファーム エス.アー. | 白金化合物の製造方法 |
| US20040044012A1 (en) | 1998-05-26 | 2004-03-04 | Dobrusin Ellen Myra | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
| US7094798B1 (en) * | 2002-04-26 | 2006-08-22 | Pfizer Inc | Inhibitors of checkpoint kinases (Wee1 and Chk1) |
| US20050250836A1 (en) * | 2004-05-03 | 2005-11-10 | Pfizer Inc | Inhibitors of checkpoint kinases (Wee1 and Chk1) |
-
2010
- 2010-02-18 CA CA2750716A patent/CA2750716A1/en not_active Abandoned
- 2010-02-18 US US13/202,773 patent/US8288396B2/en not_active Expired - Fee Related
- 2010-02-18 WO PCT/JP2010/052910 patent/WO2010098367A1/en not_active Ceased
- 2010-02-18 AU AU2010218781A patent/AU2010218781A1/en not_active Abandoned
- 2010-02-18 EP EP10746246A patent/EP2401281A4/en not_active Withdrawn
- 2010-02-18 JP JP2011535742A patent/JP2012518598A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002516327A (ja) * | 1998-05-26 | 2002-06-04 | ワーナー−ランバート・カンパニー | 細胞増殖の阻害剤としての二環式ピリミジンおよび二環式3,4−ジヒドロピリミジン |
| JP2006504632A (ja) * | 2002-04-26 | 2006-02-09 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | チェックポイントキナーゼ(Wee1およびChk1)の阻害剤 |
| WO2007126128A1 (ja) * | 2006-04-27 | 2007-11-08 | Banyu Pharmaceutical Co., Ltd. | ジヒドロピラゾロピリミジノン誘導体 |
| WO2008153207A1 (ja) * | 2007-06-15 | 2008-12-18 | Banyu Pharmaceutical Co., Ltd | ビシクロアニリン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| US8288396B2 (en) | 2012-10-16 |
| WO2010098367A1 (en) | 2010-09-02 |
| EP2401281A1 (en) | 2012-01-04 |
| AU2010218781A1 (en) | 2011-07-28 |
| US20120134955A1 (en) | 2012-05-31 |
| EP2401281A4 (en) | 2012-08-15 |
| CA2750716A1 (en) | 2010-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5167291B2 (ja) | ジヒドロピラゾロピリミジノン誘導体 | |
| EP2213673B1 (en) | Pyridone-substituted-dihydropyrazolopyrimidinone derivative | |
| US8288396B2 (en) | Pyrimidopyrimidoindazole derivative | |
| EP2168966B1 (en) | Bicycloaniline derivative | |
| JP2012511502A (ja) | ジヒドロピリミドピリミジン誘導体 | |
| JP2012511501A (ja) | ジヒドロピリミドピリミジン誘導体 | |
| CN118451077A (zh) | 双环治疗性化合物以及用于癌症的治疗的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130215 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140430 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140916 |